Behavioral and biochemical evidence for a nonessential 5-HT(2A) component of the ibogaine-induced discriminative stimulus

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 2, 1998, Pages 419-425

  Helsley, Scott ^a   Fiorella, David ^a   Rabin, R A ^a   Winter, J C ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Drug discrimination; Hallucinogen; Ibogaine; Radioligand binding; Serotonin

Indexed keywords

HARMALINE; IBOGAINE; PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR;

ALKYLATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ALKYLATING AGENTS; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; IBOGAINE; KINETICS; LYSERGIC ACID DIETHYLAMIDE; MALE; RATS; RATS, INBRED F344; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0032006544     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00451-6     Document Type: Article

References (39)

1. 2 serotonin receptor recovery J. Neu-rochem. 46:1986;589-593.
2. Colpaert F. C. Drug discrimination. Methods of manipulation, measurement, and analysis Bozarth M. A. Methods of assessing the reinforcing properties of abused drugs. 1990;341-372 Springer, Berlin.
3. Deecher D. C., Teitler M., Soderlund D. M., Bornmann W. G., Kuehne M. E., Glick S. D. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 51:1992;242-247.
4. 2C receptors in the stimulus effects of hallucinogenic drugs I. Antagonist correlation analysis Psychopharmacology (Berlin). 121:1995;347-356.
5. 2C receptors in the stimulus effects of hallucinogenic drugs II. Reassessment of LSD false positives Psychopharmacology (Berlin). 121:1995;357-363.
6. 2C receptors in the stimulus effects of hallucinogenic drugs III. The mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion Psychopharmacology (Berlin). 121:1995;364-372.
7. Fiorella D., Palumbo P A., Rabin R. A., Winter J. C. The time-dependent stimulus effects of R(-)-2,5-dimethoxy-4-methamphetamine (DOM). Implications for drug-induced stimulus control as a method for the study of hallucinogenic agents Psychopharmacology (Berlin). 119:1995;239-245.
8. 2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berlin). 119:1995;222-230.
9. Glennon R. A., Young R., Jacyno J. M., Slusher M., Rosecrans J. A. Dom-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur. J. Pharmacol. 86:1983;453-459.
10. Gozlan H., Laporte A.-M., Thubault S., Schechter L. E., Bolanos F., Hamon H. Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain. Neuropharmacology. 33:1994;423-431.
11. Helsley S., Rabin R. A., Winter J. C. The effects of 12-hydroxyibogamine and harmaline in rats trained with ibogaine as a discriminative stimulus. Life Sci. 60:1997;PL147-PL153.
12. Hough L. B., Pearl S. M., Glick S. D. Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sci. 58:1996;PL119-PL122.
13. Johnson T. L., Knowles C.O. Influence of formamidines on biogenic amine levels in rat brain and plasma. Gen. Pharmacol. 14:1983;591-596.
14. Kim J. S., Hassler R., Kurokawa M., Bak I. J. Abnormal movements and rigidity induced by harmaline in relation to striatal acetylcholine, serotonin, and dopamine. Exp. Neurol. 29:1970;189-200.
15. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
16. Mash D. C., Staley J. K., Baumann M. H., Rothman R. B., Heran W. L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 57:1995;PL45-PL50.
17. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265:1993;498-508.
18. Meller E., Goldstein M., Friedhoff A. J., Schweitzer J. W. N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). A new tool to probe CNS receptor function Adv. Exp. Med. Biol. 235:1988;121-136.
19. Naranjo, C.: Psychotropic properties of the harmala alkaloids. In Efron, D. H.; Holmstead, B.; Kline, N. S., eds. Ethnopharmacologic search for psychoactive drugs. Washington, DC: U.S. Government Printing Office; 196:385-391.
20. Nielsen E. B., White F. J., Holohean A. M., Callahan P. M., Appel J. B. Behavioral and biochemical evidence for serotonergic actions of tetrahydro-beta-carbolines. Life Sci. 31:1982;2433-2439.
21. Palumbo P. A., Witner J. C. Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD. Pharmacol. Biochem. Behav. 43:1992;1221-1226.
22. Pinto W., Battaglia G. In vivo EEDQ dose-dependently inactivates rat brain 5-HT receptors but not 5-HT uptake sites. Neuroreport. 5:1993;61-64.
23. Poirier L. J., Singh P., Boucher R. Opposite effect of harmaline on serotonin and on dopamine and its metabolites, homovanillic acid and norepinephrine, in the brain of the cat. Can. J. Physiol. Pharmacol. 46:1968;585-589.
24. Popik P., Layer R. T., Skolnick P. 100 years of ibogaine. Neurochemical and pharmacological actions of a putative anti-addictive drug Pharmacol. Rev. 4:1995;235-253.
25. Repke D. B., Artis D. R., Nelson J. T. Abbreviated ibogaine congeners. Synthesis and reactions of tropan-3-yl-2-and-3-indoles. Investigation of a unusual isomerization of 2-substituted indoles using computational and spectroscopic techniques. J. Org. Chem. 59:1994;2164-2171.
26. Robertson H. A. Harmaline-induced tremor. The benzodiazepine receptor as a site of action Eur. J. Pharmacol. 67:1980;129-132.
27. Schechter M. D., Gordon T. L. Comparison of the behavioral effects of ibogaine from three sources. Mediation of discriminative activity Eur. J. Pharmacol. 249:1993;79-84.
28. Sheppard S. G. A preliminary investigation of ibogaine. Case reports and recommendations for further study J. Subst. Abuse Treat. 11:1994;379-385.
29. Singh P., Poirier L. J., Boucher R. Effect of monoamine oxidase inhibitors on the concentration of dopamine and serotonin in the striatum of the cat with and without unilateral brainstem lesions. Can. J. Physiol. Pharmacol. 45:1967;897-904.
30. Sloviter R. S., Drust E. G., Damiano B. P., Connor J. D. A common mechanism for lysergic acid, indole alkylamine, and phenethylamine hallucinogens. Serotonergic mediation of behavioral effects in rats J. Pharmacol. Exp. Ther. 214:1980;231-238.
31. Staley J. K., Ouyang Q., Pablo J., Hearn W. L., Flynn D. D., Rothman R. B., Rice K. C., Mash D. C. Pharmacological screen for activities of 12-hydroxyibogamine. A primary metabolite of the indole alkaloid ibogaine Psychopharmacology (Berlin). 127:1996;10-18.
32. Stolerman I. P., Shine P. J. Trends in drug discrimination research analysed with a cross-indexed bibliography. Psychopharmacology (Berlin). 86:1985;1-11.
33. Sweetnam P. M., Lancaster J., Snowman A., Collins J. L., Perschke S., Bauer C., Ferkany J. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology (Berlin). 118:1995;369-376.
34. Udenfriend S., Witkop B., Redfield B. G., Weissbach H. Studies with reversible inhibitors of monoamine oxidase. Harmaline and related compounds Biochem. Pharmacol. 1:1958;160-165.
35. Winter J. C. Drug induced stimulus control. Blackman D. E., Sangar D. J Contemporary research in behavioral pharmacology. 1978;209-237 Plenum, New York.
36. Winter J. C. The stimulus properties of para-methoxyamphetamine. A nonessential serotonergic component Pharmacol. Biochem. Behav. 20:1984;201-203.
37. Winter J. C. The stimulus effects of serotonergic hallucinogens in animals. NIDA Res. Monog. 146:1994;157-182.
38. Winter J. C., Rabin R. A. Yohimbine as a serotonergic agent. Evidence from receptor binding and drug discrimination J. Pharmacol. Exp. Ther. 263:1992;682-689.
39. Zetler G., Singbartl G., Schlosser L. Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharamcology (Berlin). 7:1972;237-248.